Cargando…
First-in-human Phase 1 CRISPR Gene Editing Cancer Trials:Are We Ready?
A prospective first-in-human Phase 1 CRISPR gene editing trial in the United States for pa-tients with melanoma, synovial sarcoma, and multiple myeloma offers hope that gene editing tools may usefully treat human disease. An overarching ethical challenge with first-in-human Phase 1 clinical trials,...
Autores principales: | Baylis, Françoise, McLeod, Marcus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769084/ https://www.ncbi.nlm.nih.gov/pubmed/29173170 http://dx.doi.org/10.2174/1566523217666171121165935 |
Ejemplares similares
-
Gene Editing with CRISPR/Cas Methodology and Thyroid Cancer: Where Are We?
por: Fuziwara, Cesar Seigi, et al.
Publicado: (2022) -
Functional profiling of single CRISPR/Cas9-edited human long-term hematopoietic stem cells
por: Wagenblast, Elvin, et al.
Publicado: (2019) -
First Report of CRISPR/Cas9 Gene Editing in Castanea sativa Mill
por: Pavese, Vera, et al.
Publicado: (2021) -
Shining Light on CRISPR Gene Editing
por: Taemaitree, Lapatrada, et al.
Publicado: (2020) -
Gene therapy – are we ready now?
por: Kaczmarek, Radoslaw
Publicado: (2022)